Author Archives: Patricia Inacio PhD

Arrowhead Asks to Open Phase 1/2 Trial into Inhaled RNAi Therapy

Arrowhead Pharmaceuticals has filed for approval to launch a Phase 1/2a clinical trial in New Zealand testing its candidate inhaled therapy for cystic fibrosis (CF), called ARO-ENaC, the company announced. ARO-ENaC is an investigational RNA therapy designed to lower the production of the epithelial sodium channel alpha subunit (αENaC) in the…


Featured Column

How I Discovered That PTSD Was Causing My Post-transplant Struggles

PTSD, mental health, communities, stress, grateful, work, trauma, rare disease day, transplant, CF community, National Blood Donor Month, birthdays, holidays
Columnist Lara Govendo addresses an issue that several readers may relate to: post-transplant PTSD, which can wreak havoc.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.